L3VLUP
ProSign in

UTHR · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

UTHRLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • UTHR
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterUTHRLLY
Q3 202010 holders, $797m33 holders, $14.1bn
Q4 202011 holders, $1.2bn29 holders, $17.3bn
Q1 202110 holders, $1.4bn24 holders, $23.0bn
Q2 202111 holders, $1.5bn24 holders, $27.8bn
Q3 202116 holders, $1.5bn31 holders, $29.9bn
Q4 202114 holders, $1.9bn31 holders, $34.7bn
Q1 202214 holders, $1.7bn24 holders, $35.3bn
Q2 202218 holders, $2.3bn33 holders, $42.7bn
Q3 202217 holders, $2.2bn31 holders, $43.4bn
Q4 202218 holders, $2.9bn31 holders, $46.6bn
Q1 202316 holders, $2.5bn33 holders, $44.3bn
Q2 202312 holders, $2.5bn37 holders, $59.6bn
Q3 202313 holders, $2.4bn44 holders, $67.6bn
Q4 202314 holders, $2.3bn45 holders, $73.6bn
Q1 202419 holders, $2.2bn41 holders, $95.3bn
Q2 202414 holders, $2.5bn43 holders, $110bn
Q3 202410 holders, $2.9bn45 holders, $107bn
Q4 202414 holders, $3.3bn46 holders, $93.9bn
Q1 202514 holders, $2.1bn42 holders, $98.4bn
Q2 202514 holders, $1.9bn43 holders, $93.2bn
Q3 202516 holders, $2.6bn39 holders, $86.7bn
Q4 202514 holders, $3.8bn41 holders, $123bn
Q1 202618 holders, $5.1bn39 holders, $106bn
Q2 202614 holders, $3.5bn44 holders, $132bn
UTHR

United Therapeutics Corp Del

Holders
14
Reported value
$3.8bn
Buyers
17
Sellers
20

Breadth -3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only UTHR (3)

Baillie Gifford & Co, ExodusPoint Capital Management LP, Schonfeld Strategic Advisors LLC

Only LLY (30)

Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Marshall Wace LLP, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, Steadfast Capital Management LP, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →